Zasocitinib achieved superior skin clearance compared with deucravacitinib in a Phase 3 psoriasis trial, according to a report published by Dermatology Times. The headline finding positions the investigational agent ahead of an approved oral tyrosine kinase 2 (TYK2) inhibitor in a direct comparative setting — a study design that remains relatively uncommon in plaque psoriasis drug development.

The trial compared the two molecules head-to-head, with skin clearance serving as the primary basis for the superiority claim. Dermatology Times did not report the specific clearance endpoint values in its headline announcement — data such as PASI 75, PASI 90 or PASI 100 response rates, or sPGA outcomes, are expected to surface with fuller presentation of the results.

Why the comparator matters

Deucravacitinib, the comparator in this study, is an allosteric TYK2 inhibitor approved for the treatment of moderate to severe plaque psoriasis in adults. It established its efficacy in the POETYK PSO program, where it outperformed both placebo and apremilast on PASI 75 and sPGA 0/1 endpoints. Beating deucravacitinib in a controlled head-to-head trial therefore sets a higher evidentiary bar than demonstrating superiority over placebo or an older oral agent.

Zasocitinib, the investigational drug in this trial, is likewise a TYK2-directed therapy, according to the report. The TYK2 pathway has become a focal point in psoriasis drug development because it sits upstream of the IL-23 and IL-12 signaling cascades that drive the disease, while offering an oral route of administration compared with biologic injectables.

What remains to be seen

A superiority claim on skin clearance answers one question but leaves several open. The dermatology community will want the magnitude of the effect — the difference in PASI response rates between the two arms, the confidence intervals, and the week at which the primary endpoint was measured.

Safety and tolerability data will carry particular weight in this comparison. Deucravacitinib's label reflects a favorable safety profile that supported its approval, including no requirement for routine laboratory monitoring of the kind associated with JAK inhibitors targeting JAK1, JAK2 and JAK3. For zasocitinib to displace an established oral therapy in clinical practice, its safety profile will need to match its efficacy advantage.

Dosing convenience, drug–drug interactions and patient-selection criteria will also shape how the results translate into practice, assuming the data support registration.

Competitive context

Oral systemic therapy for moderate to severe psoriasis is a crowded and intensifying field. Apremilast has long held a place in the treatment algorithm, deucravacitinib raised the ceiling for oral efficacy, and multiple TYK2 and other orally administered candidates are advancing through late-stage pipelines. A Phase 3 win over the current class benchmark would give zasocitinib a differentiated claim no placebo-controlled trial could provide.

The competitive dynamics in psoriasis have historically been driven by head-to-head biologic trials, with IL-17 and IL-23 agents competing on PASI 90 and PASI 100 response rates. An oral-versus-oral head-to-head with superiority on skin clearance extends that same evidentiary logic into the small-molecule space.

Looking ahead

Fuller results — including endpoint definitions, response rates and safety tables — are expected at an upcoming medical congress or in a peer-reviewed publication, and those disclosures will determine whether zasocitinib's Phase 3 superiority translates into a registration filing and, ultimately, a new standard for oral psoriasis therapy.